Clinical Trial Update: Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating a combination of lenalidomide, cytarabine, and idarubicin in adults with acute myeloid leukemia; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
• Acute Myeloid Leukemia with Inv Cbfb-myh11 Rearrangement
• Acute Myeloid Leukemia with Mllt3-mll
• Acute Myeloid Leukemia with Runx1-runx1t1
• Acute Promyelocytic Leukemia
• Untreated Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Idamycin (idarubicin)
• Revlimid (lenalidomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Phase 1 | Status: COMPLETED